SCHEMBL12189232

SCHEMBL12189232

CCc1ccc(S(=O)(=O)N2CCC(O)CC2)cc1

nearest known ligand 0.72

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.72
LMNA P02545 2/20 0.65
L3MBTL1 Q9Y468 1/20 0.65
HSD11B1 P28845 3/20 0.58
THRB P10828 1/20 0.52
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
HTT P42858 1/20 0.50
USP2 O75604 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
DDIT3 P35638 1/20 0.49
KCNH2 Q12809 1/20 0.49
HRH3 Q9Y5N1 1/20 0.49
NAMPT P43490 1/20 0.48
TP53 P04637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12188944 0.91 ALDH1A1 (0.64) ALDH1A1LMNAL3MBTL1HSD11B1THRB
SCHEMBL12188938 0.86 ALDH1A1 (0.70) ALDH1A1LMNAL3MBTL1HSD11B1THRB
SCHEMBL15215001 0.83 ALDH1A1 (0.66) ALDH1A1LMNAL3MBTL1HSD11B1THRB
SCHEMBL20885033 0.82 ALDH1A1 (0.51) ALDH1A1LMNAL3MBTL1HSD11B1MEN1
SCHEMBL12646351 0.82 TP53 (0.58) ALDH1A1LMNAL3MBTL1HSD11B1KCNH2
SCHEMBL4940237 0.82 ALDH1A1 (0.64) ALDH1A1LMNAHSD11B1MEN1KMT2A
SCHEMBL4480464 0.82 ALDH1A1 (0.63) ALDH1A1LMNAL3MBTL1HSD11B1THRB
SCHEMBL12646347 0.82 USP2 (0.68) ALDH1A1LMNAL3MBTL1HSD11B1THRB
SCHEMBL12189227 0.80 USP2 (0.71) ALDH1A1LMNAL3MBTL1HSD11B1THRB
SCHEMBL12793343 0.80 USP2 (0.71) ALDH1A1LMNAHSD11B1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3440084-B1 PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING PI3K-MEDIATED DISORDERS DANA FARBER CANCER INST INC (US) 2022-12-21 EP disclosed
US-20120322798-A1 Modulators of ATP-Binding Cassette Transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-12-20 US disclosed
US-20120232059-A1 Modulators of ATP-Binding Cassette Transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-09-13 US disclosed
US-7956052-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-06-07 US disclosed
US-7741321-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-06-22 US disclosed
US-20080113985-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2008-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120322798-A1 Modulators of ATP-Binding Cassette Transporters CFTR, ABCB1, ABCC2 ALDH1A1 1991/4885LMNA 3485/4885L3MBTL1 3323/4885
US-20080113985-A1 Modulators of ATP-binding cassette transporters CFTR, ABCB1, ABCC2 ALDH1A1 1786/4885LMNA 3535/4885L3MBTL1 3641/4885
US-20120232059-A1 Modulators of ATP-Binding Cassette Transporters CFTR, ABCB1, ABCC2 ALDH1A1 1786/4885LMNA 3535/4885L3MBTL1 3641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.